Autori: Moiseenko FV
| Naslov | 3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer (Meeting Abstract) |
| Autori | Verschraegen C Andric Zoran G Moiseenko FV Makharadze T Oleksiienko A Ruiz EP Yanez Kim SH Ahn K Park TH Ju HA Baek EH Kwon S Lee SJ Chang I Kim SH Kim HA Lee E Ohe Y |
| Info | ANNALS OF ONCOLOGY, (2024), vol. 35 br. , Suppl. 4, str. S1648-S1649 |
| Projekat | Celltrion Inc. |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | POD1UM-304: Phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic nonesmall cell lung cancer (mNSCLC) (Meeting Abstract) |
| Autori | Lu S Vynnychenko O Kulyaba Y Kuchava V Ibrahim A Moiseenko FV Arslan C Nguyen DT Zhang M Petrovic MD Cicin I Bibichadze K Cil T Cornfeld M Tian C Munteanu M Sette CVDM Bondarenko I |
| Info | ANNALS OF ONCOLOGY, (2024), vol. 35 br. , Suppl. 4, str. S1633-S1634 |
| Projekat | Incyte Corporation, Wilmington, DE, USA |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
